Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) EBIT Margin (2019 - 2025)

Eton Pharmaceuticals' EBIT Margin history spans 7 years, with the latest figure at 3.56% for Q3 2025.

  • For Q3 2025, EBIT Margin fell 849.0% year-over-year to 3.56%; the TTM value through Sep 2025 reached 1.25%, up 604.0%, while the annual FY2024 figure was 2.05%, 159.0% down from the prior year.
  • EBIT Margin for Q3 2025 was 3.56% at Eton Pharmaceuticals, up from 7.79% in the prior quarter.
  • Across five years, EBIT Margin topped out at 87.41% in Q4 2022 and bottomed at 754.45% in Q3 2021.
  • The 5-year median for EBIT Margin is 7.8% (2023), against an average of 58.55%.
  • The largest YoY upside for EBIT Margin was 2261419bps in 2021 against a maximum downside of -24731177bps in 2021.
  • A 5-year view of EBIT Margin shows it stood at 21.57% in 2021, then skyrocketed by 305bps to 87.41% in 2022, then crashed by -104bps to 3.17% in 2023, then surged by 756bps to 20.83% in 2024, then tumbled by -117bps to 3.56% in 2025.
  • Per Business Quant, the three most recent readings for ETON's EBIT Margin are 3.56% (Q3 2025), 7.79% (Q2 2025), and 31.33% (Q1 2025).